Table 1.
Patient characteristics
| Characteristic | Total cohort (n = 31) |
|---|---|
| Age, median (range), y | 61 (23-79) |
| Female, n (%) | 11 (36) |
| Diagnosis, n (%) | |
| DLBCL | 25 (81) |
| PMBCL | 2 (7) |
| PCNS lymphoma | 1 (3) |
| Burkitt | 1 (3) |
| cBALL | 1 (3) |
| MCL | 1 (3) |
| CAR-T cell product, n (%) | |
| Axicabtagene ciloleucel | 20 (64) |
| Tisagenlecleucel | 7 (23) |
| Allogeneic | 3 (10) |
| Brexucabtagene autoleucel | 1 (3) |
| Bridging therapy, n (%) | |
| No | 7 (23) |
| Yes | 24 (77) |
| CRS grade, n (%) | |
| 0 | 1 (3) |
| 1-2 | 25 (81) |
| 3-4 | 5 (16) |
| Neurotoxicity grade, n (%) | |
| 0 | 10 (32) |
| 1-2 | 13 (42) |
| 3-4 | 8 (26) |
| Time to boost in months, median (range) | 1.45 (0.2-14.6) |
| CD34+ progenitors × 106/kg BW, median (range) | 3.6 (1.1-11.5) |
| ANC at time of lymphodepletion × 109/L, median (range) | 2.9 (1.8-9.5) |
| ANC at time of boost × 109/L, median (range) | 0.2 (0-2.0) |
| Platelets at time of boost × 109/L, median (range) | 12 (0-30) |
| Hemoglobin at time of boost × g/dL, median (range) | 9.0 (6.1-11.8) |
| Transfusion dependence at time of boost, n (%) | 12 (39) |
Abbreviations: ANC, absolute neutrophile count; BW, body weight; CAR-T, chimeric antigen receptor T-cell therapy; cBALL, common B acute lymphoblastic leukemia; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; PCNS, primary central nervous system; PMBCL, primary mediastinal B-cell lymphoma.